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Currently, there are no compendial in vitro release tests specifically indicated for parenteral 24 
formulations. Consideration of biorelevant and clinically relevant test media represents a 25 
valuable approach for the development of in vitro tests that ideally can provide information on 26 
the formulation performance in vivo. The aim of this study was to investigate the effect of 27 
different media components on the solubility of Amphotericin B (a poorly soluble highly 28 
protein-bound drug) in order to develop biorelevant and clinically relevant media for future in 29 
vitro release testing from its liposomal formulation. Three categories of media were considered 30 
in the development approach: Category 1 media: effect of albumin concentration; category 2 31 
media: effect of biorelevant concentrations of plasma components (bile salts, phospholipids, 32 
cholesterol, albumin); category 3 media: attaining clinically relevant solubility with biorelevant 33 
and synthetic surfactants with and without albumin and setting the basis for the development 34 
of a simulated hypoalbuminaemic plasma medium. All the surfactants tested increased 35 
Amphotericin B solubility while the simultaneous presence of albumin had a negative effect 36 
on solubility. Clinically relevant media with the use of biorelevant or synthetic surfactants and 37 
albumin were developed. One medium in which the solubility of Amphotericin B was reduced 38 
was identified as potential candidate medium to simulate hypoalbuminaemic plasma. The 39 
development of biorelevant and clinically relevant media and understanding the effect of media 40 
components and their interactions, supports future development of meaningful in vivo 41 
predictive release tests for parenteral formulations. 42 
 43 
Keywords: 44 




1. Introduction. 47 
Recently, the development of parenteral formulations (for drugs of low aqueous solubility and 48 
toxic drugs) has grown. Currently, there is no in vitro compendial method specifically assessing 49 
how changes to a formulation might result in a change in in vivo performance of a parenteral 50 
drug product (Allen, 2014; D'Souza and DeLuca, 2006; Seidlitz et al., 2011; Shen and Burgess, 51 
2012, 2013). The in vitro dissolution/release testing used in quality control does not provide 52 
information about the dissolution/release of the drug in the environment where the formulations 53 
will be administered (such as the intravenous, intramuscular and subcutaneous routes (Allen, 54 
2014)). Biorelevant dissolution testing refers to an attempt to mimic the conditions of the in 55 
vivo environment in terms of the composition and physicochemical characteristics of the in 56 
vivo fluids and the hydrodynamics at the site of administration (Wang et al., 2009). Recently, 57 
clinically relevant dissolution testing has been defined; the term “clinically relevant” implies 58 
the establishment of a link between a drug product quality attribute (e.g. solubility) and in vivo 59 
performance (e.g. in vivo solubility) (Abend et al., 2018; Norris, 2016). This terminology has 60 
been agreed in a workshop organised by US FDA and the International Consortium for 61 
Innovation and Quality in Pharmaceutical Development (IQ) (Abend et al., 2018). A clinically 62 
relevant approach to dissolution testing enables dissolution testing to establish safe boundaries 63 
and reject drug product batches falling outside the established safe range (Abend et al., 2018). 64 
Another aspect that is not usually covered in compendial in vitro release testing in terms of the 65 
media composition is the variation in in vivo physiological conditions induced by illness. In 66 
addition to simulating the fluid where the formulation will be administered, these physiological 67 
changes should, when appropriate, be reflected in the test medium. From previous studies, our 68 
group has developed a biorelevant test medium that simulates plasma (using Krebs Ringer 69 
Buffer (KRB) (Cold Spring Harbor Protocols, 2014) for the ionic content and bovine serum 70 
albumin (BSA) to represent the human serum albumin) which was used to evaluate the impact 71 
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of albumin concentration on the solubility and degradation of Amphotericin B (AmB) (Diaz de 72 
Leon-Ortega et al., 2018). AmB, a highly protein-bound (including to albumin and lipoproteins 73 
(Barwicz et al., 1998; Brajtburg et al., 1984; Ridente et al., 1999)) and poorly soluble drug 74 
(Torrado et al., 2008), was selected as a model drug as it is commercially available as parenteral 75 
lipid-based formulations (including Ambisome® and Abelcet®) for intravenous administration. 76 
AmB formulations can be used in patients suffering from severe systemic fungal infections. 77 
The presentation of sepsis in critically ill patients can include a reduced plasma albumin 78 
concentration (hypoalbuminaemia), thus hypoalbuminaemia is a potential feature of the 79 
vascular fluid into which AmB is administered in vivo. The aim of this study was to investigate 80 
the impact of different media components on the solubility and degradation of AmB to develop 81 
media able to target AmB plasma solubility (clinically relevant solubility) and to evaluate if 82 
the composition of a medium is suitable for future compendial in vitro release testing. Media 83 
were developed based on three categories (Figure 1). Category 1 media: biorelevant media, 84 
investigating the impact of concentration of BSA. Category 2 media: Biorelevant media, 85 
investigating the impact of biorelevant concentrations of plasma components to which AmB 86 
binds in vivo [cholesterol, bile salts and phospholipids, with and without BSA]. Category 3 87 
media: Clinically relevant media; category 3a media- attaining clinically relevant solubility 88 
with physiological surfactants found in plasma (bile salts and phospholipids); Category 3b 89 
media- attaining clinically relevant solubility with synthetic surfactants (SLS, CTAB or Tween 90 
80); Category 3c media- potential for category 3b media to be used as a basis to develop media 91 
for solubility and release studies simulating hypoalbuminaemic plasma. In advance of 92 
performing clinically relevant release testing, the development of biorelevant and clinically 93 
relevant test media (based on the active pharmaceutical ingredient (API)) is a primary step 94 
towards the development of biorelevant and clinically relevant release testing of parenteral 95 
formulations. Additionally, whereas API dissolution rates might not be considered directly 96 
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relevant to intravascular parenteral administration, API dissolution studies were performed in 97 
the current work in order to identify any factors affecting the solubility behaviour of the drug 98 
in the test media over time. This is an important step in the development of release testing of 99 
parenteral formulations, as issues relating to API precipitation, for example, may be easier to 100 
identify in a simper API dissolution test in advance of formulation release testing. 101 
2. Materials and Methods 102 
2.1. Materials 103 
AmB analytical standard (87.8%), methanol (MeOH) high performance liquid chromatography 104 
(HPLC) grade, formic acid mass spectrometry grade, NaOH, MgCl2, CaCl2, 105 
hexadecyltrimethylammonium bromide (CTAB), cholesterol (CH), NHCO3 and NH4HCO2 106 
were obtained from Sigma Aldrich (Germany); ethylenediaminetetracetic acid anhydrous 107 
(EDTA) from Sigma Aldrich (USA); AmB API powder (85%) from Cayman Chemical (USA); 108 
BSA protease free powder fraction V, dimethyl sulfoxide (DMSO), dextrose, sodium dodecyl 109 
sulphate (SLS), Na2HPO4, NaH2PO4, KH2PO4, NaCl and KCl from Fisher Scientific (USA); 110 
Tween 80 from Amresco (USA); phosphatidylcholine from egg from Lipoid GmbH 111 
(Germany); sodium taurocholate from Prodotti Chimici e Alimentaria (Italy); GF/D (pore size 112 
2.7 μm, 25 mm diameter) and GF/F (pore size 0.7 μm, 25 mm diameter) filters from Whatman 113 
(UK) and regenerated cellulose (RC) filters 0.45 µm 13 mm diameter from Cronus (UK). 114 
2.1.1. Human plasma collection 115 
Blood was drawn from healthy volunteers (having given informed consent) by median cubital 116 
vein venipuncture by a trained phlebotomist following local ethics committee approval 117 
(EIRA1, Issue 3, 11/5/2010). To act as anticoagulant, 2 mL of an EDTA 50 mg/mL solution 118 
were added to a final volume of 50 mL of blood, for a final concentration of 2 mg/mL. Plasma 119 
was separated from blood cells by centrifugation for 10 min at 2000 x g (Heraeus Biofuge 120 
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Primo R Centrifuge, Thermo Electron LED GmbH. Osterode, Germany) and the supernatant 121 
was separated into aliquots and kept at -80°C.  122 
2.2. Sample treatment of AmB in plasma and test media 123 
The sample treatment method was described previously (Diaz de Leon-Ortega et al., 2018). 124 
Briefly, proteins were precipitated by adding 2 volumes of methanol to 1 volume of the sample 125 
followed by mixing in a vortex mixer and centrifuged for 10 minutes at 12000 rpm at 5°C. The 126 
supernatant was filtered through a 0.45 μm RC filter before injection to the HPLC. 127 
2.3. Chromatographic conditions for the analysis of AmB from plasma samples and test 128 
media 129 
The chromatographic method to quantify AmB was described previously (Diaz de Leon-Ortega 130 
et al., 2018). Briefly, AmB was quantified by HPLC with a C18 Waters Sunfire column 131 
(Ireland) 150 x 46 mm 5 μm at 25°C. The mobile phase was formate buffer (50 mM; pH = 3.2): 132 
MeOH (25:75, v/v); the flow rate was 1 mL/min and AmB was detected at λ = 406 nm. The 133 
UV spectrum was recorded from 300 to 450 nm. Quantification of AmB in samples was based 134 
on standard curves. Freshly prepared standard solutions (0.5 – 15 μg/mL) in the corresponding 135 
medium were prepared by appropriate dilution of a 500 μg/mL stock solution of AmB 136 
analytical standard in 1:1 MeOH: DMSO v/v. The limit of detection and the limit of 137 
quantification were 0.12 and 0.37 μg/mL, respectively. 138 
2.4. Test media for evaluation of performance of parenteral drug products 139 
Media were developed following the scheme of the 3 categories of development (Figure 1).  140 
2.4.1. Category 1 media: investigating the impact of albumin concentration 141 
Category 1 media consisted of KRB with varying biorelevant albumin concentrations and were 142 
developed and characterized as previously described (Diaz de Leon-Ortega et al., 2018). BSA 143 
was used as a substitute for human serum albumin as it has been reported that there is only one 144 
favourable binding site for AmB in both of them (Kudva et al., 2011). 145 
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2.4.2. Category 2 media: investigating the effect of biorelevant concentrations of plasma 146 
components on AmB solubility 147 
Plasma components with the potential to affect the solubility of AmB in vivo, were added to 148 
KRB in biorelevant concentrations: bile salts 12.0 μM (mean value of the highest 149 
concentrations reported in literature (Ambros-Rudolph et al., 2007; Egan et al., 2012; 150 
Hospitals, 2014)); phospholipids 2.5 mM (Salvioli et al., 1985; Schaefer et al., 1958) and CH 151 
4.5 mM (Abdelmagid et al., 2015). For media preparation, bile salts [sodium taurocholate was 152 
used as source of bile salts (BS)] were weighed and dissolved in KRB and then phospholipids 153 
[phosphatidylcholine from egg was used as source of phospholipids (PL)] from a stock solution 154 
of 100 mg/mL (dissolved in dichloromethane) were added; afterwards, where relevant, CH 155 
dissolved in chloroform (3.5 mg/mL) was added to the medium. Organic solvents were 156 
evaporated with a rotary evaporator consisting of a Büchi Waterbath B-480 set at 40°C and a 157 
Büchi Rotovapor R-114 (Büchi Labotechnik. Flawil, Switzerland) attached to a vacuum pump 158 
unit PC 2001 Vario (Vacuubrand GMBH. Wertheim, Germany). The pressure was decreased 159 
from 650 mbar in steps of 70 mbar every two minutes to 100 mbar, where the pressure was 160 
maintained for 10 minutes. When included in the medium, BSA (2.0% and 4.0% w/v as 161 
biorelevant concentrations) was added after the evaporation of the organic solvents. A medium 162 
with a high concentration (8.0% w/v) BSA was also tested. The compositions of the media are 163 
listed in Table 2 (Category 2 media). Osmolality, viscosity, pH and buffer capacity of these 164 
media were measured (section 2.5) and AmB solubility studies (section 2.7) were also 165 
performed in these media. 166 
2.4.3. Category 3 media: investigating the impact of biorelevant and synthetic surfactants 167 
to achieve clinically relevant AmB solubility  168 
Media were developed to achieve clinically relevant solubility values of AmB by using 169 
surfactants found in plasma (BS and PL) and synthetic surfactants (SLS, CTAB, Tween 80). 170 
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The effect of BSA was also evaluated (media with and without BSA 4.0% w/v). Media with 171 
synthetic surfactants were investigated for potential to simulate hypoalbuminaemic plasma. 172 
2.4.3.1. Category 3a: Biorelevant surfactants 173 
Attaining clinically relevant solubility with surfactants found in plasma (BS and PL), with and 174 
without BSA.  175 
In order to evaluate the impact of BSA concentration and biorelevant surfactants on AmB 176 
solubility, media with BS, PL and BSA were prepared. The use of phosphate buffer saline 177 
(PBS) (Cold Spring Harbor Protocols, 2007) as a simpler buffer solution than KRB was also 178 
investigated as a basis for media development. A 2 level factorial design of experiments (DoE) 179 
was used to identify which factors had a significant effect on AmB solubility. Factors 180 
investigated were type of buffer: PBS or KRB; BS concentration: 3.0 or 10.0 mM; and PL 181 
concentration: 0.2 or 3.0 mM. The BS concentrations were selected to represent a wide range, 182 
including concentrations higher than the biorelevant concentration, with all investigated 183 
concentrations being higher than the critical micelle concentration of the surfactants. The PL 184 
concentration was set in order that the PL/ (BS+PL) molar fraction was lower than 0.6, which 185 
is the necessary for mixed micelles formation (Moschetta et al., 2001). Eight experimental 186 
setups resulted from the combination of these factors, BSA 4.0% w/v was added to all media, 187 
and solubility studies were performed in the 8 media. After the identification of the statistically 188 
significant factors affecting AmB solubility, the compositions of clinically relevant media were 189 
predicted with a DoE (section 2.10) which targeted AmB solubility in plasma. AmB solubility 190 
studies were then conducted in these predicted media for comparison with AmB plasma 191 
solubility values to validate the prediction. To investigate how BSA affects AmB solubility in 192 
the presence of the biorelevant surfactants, the predicted media were also prepared without 193 
BSA. Media characterization, AmB degradation and solubility studies were performed in the 194 
developed media with and without BSA (section 2.5, 2.6 and 2.7). 195 
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2.4.3.2. Category 3b: Synthetic surfactants 196 
Attaining clinically relevant solubility with synthetic surfactants with and without BSA.  197 
KRB and PBS were tested with 3 different types of surfactants: SLS (anionic surfactant), 198 
CTAB (cationic surfactant) and Tween 80 (non-ionic surfactant). The critical micelle 199 
concentration (CMC) of charged surfactants was determined in PBS and KRB by 200 
conductimetry (Conductivity Meter, WPA CMD 500, Scientific Laboratory Supplies Ltd, UK) 201 
to assure that the concentrations selected were above the CMC. 1 mL of a 10.0 mM solution of 202 
the surfactant in the corresponding buffer was added to either 20 mL (for SLS) or 50 mL (for 203 
CTAB) of the same buffer and the conductivity recorded. Conductivity was plotted against the 204 
surfactant concentration and the CMC was established when there was a sudden change in the 205 
slope. Measurements were performed in triplicate. Tween 80 CMC is not affected by the ionic 206 
composition of the buffer and the CMC value reported in literature was used (Sigma-Aldrich, 207 
2019). To study the effect of the surfactants on AmB solubility, the surfactant concentrations 208 
investigated were 5.0, 50.0 and 100.0 mM with and without BSA 4.0% w/v. Single point AmB 209 
solubility experiments were conducted in all the media following the procedure described in 210 
section 2.7, with 1 mg of AmB API powder added in 10 mL of medium and sampling at 12 h, 211 
as a solubility plateau value was reached around 12 h in previous solubility determinations 212 
(Diaz de Leon-Ortega et al., 2018). The media with the surfactant resulting in an AmB 213 
solubility value closest to the AmB plasma solubility, with and without BSA, were selected to 214 
develop the clinically relevant media. Surfactant concentrations, in the range where media 215 
demonstrated the clinically relevant AmB solubility value, were investigated in order to obtain 216 
the surfactant concentration to produce clinically relevant AmB solubility by performing single 217 
point solubility experiments at 12 h in those ranges. Media characterization, degradation and 218 
solubility studies (section 2.5, 2.6 and 2.7) were performed in the developed media. 219 
2.4.3.3. Category 3c: Potential media to simulate hypoalbuminaemic patients. 220 
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Potential for media with synthetic surfactants and BSA, to be used as a basis to develop media 221 
simulating hypoalbuminaemic plasma. 222 
In order to identify conditions that could direct future hypoalbuminaemic medium 223 
development, clinically relevant medium in PBS from category 3b was used as a base. For 224 
these studies there was no target solubility value as a reference AmB solubility in 225 
hypoalbuminaemic plasma is not available. In order to mimic hypoalbuminaemic plasma, the 226 
use of PBS was explored with a) 2.0% w/v BSA and the corresponding concentration of 227 
surfactant developed as clinically relevant medium in category 3b, b) 2.0% w/v BSA with half 228 
of the concentration of surfactant from category 3b media and c) 4.0% w/v BSA with half of 229 
the concentration of surfactant from category 3b media. Media characterization, degradation 230 
studies (section 2.5 and 2.6) and single point solubility studies as described in section 2.4.3.2 231 
were performed in the media. 232 
2.5. Test media characterization 233 
Media characterization methodology was described previously (Diaz de Leon-Ortega et al., 234 
2018). Briefly, pH was measured in all the media following addition of all components. 235 
Osmolality was measured via the freezing-point depression method with a Micro-Osmometer 236 
3300 (Advanced Instruments, Massachusetts USA). Viscosity of all media was measured with 237 
a Bohlin Rheometer (Germany) at 25°C in triplicate. Buffer capacity was determined by adding 238 






𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
 𝑜𝑣𝑒𝑟 𝑟𝑎𝑛𝑔𝑒 𝑖𝑛𝑣𝑜𝑙𝑣𝑒𝑑
)(∆𝑝𝐻)




 is the buffer capacity, [𝐻𝐶𝑙] is the concentration of hydrochloric acid and ∆𝑝𝐻 is 241 
the pH increment. The measurement was performed in triplicate. 242 
The media were graded based on their complexity and received values from 1 to 4, being 1 to 243 
the simplest and 4 the most complex medium. The scale was based on the number of 244 
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components to prepare the medium (1 for PBS, 2 for KRB) and on the ease of preparation (1 245 
for mixing the components, 2 for mixing components and evaporating solvents). 246 
2.6. Degradation rate constant determination of AmB in plasma and in test media 247 
The degradation rate constant determination methodology was described previously (Diaz de 248 
Leon-Ortega et al., 2018). Briefly, 3 mg of AmB API powder was added to 20 mL of plasma 249 
and then stirred for 1 hour at 130 rpm at 37°C. Samples were centrifuged for 5 minutes at 3000 250 
rpm at 4°C and the supernatant incubated at 37°C. Samples were taken at 0.5, 1.0, 1.5, 2.0, 3.0, 251 
4.0, 5.0, 6.0, 8.0 and 24.0 hours, and analysed as described in section 2.3. AmB in the samples 252 
was determined. For dissolution media, the same procedure was followed with 10 mg of AmB 253 
API powder added to 50 mL of dissolution media and monitored for 8 hours. All experiments 254 
were performed in triplicate. A linear fit was applied to the degradation data from 4 h to the 255 
last time point, after a natural logarithm transformation of the measured concentration (Excel 256 
2013) and the degradation rate constant (𝑘𝑑𝑒𝑔) was calculated as the slope of the line.  257 
2.7. Solubility studies of AmB in plasma and in test media 258 
Solubility study methodology was described previously (Diaz de Leon-Ortega et al., 2018). 259 
Briefly, approximately 2.5 mg of AmB API powder were placed in a 100 mL glass bottle with 260 
30 mL of the corresponding dissolution media, stirred at 130 rpm and incubated at 37°C. The 261 
sampling times were 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0 and 24.0 hours. The 262 
undissolved AmB was removed by centrifugation and after protein precipitation and samples 263 
were analysed as described in section 2.3. Solubility studies in plasma were performed with 264 
1.5 mg of AmB in 10 mL of plasma. Solubility studies in media with synthetic surfactants 265 
(single point solubility at 12 h) were performed with ~1 mg of AmB in 10 mL of medium. The 266 
AmB solubility saturation value was considered when the concentration reached a plateau 267 
value. An AmB solubility value in the dissolution media similar to the AmB plasma solubility 268 
was considered "clinically relevant". All experiments were performed in triplicate. 269 
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2.8. Dissolution studies of AmB in clinically relevant media from category 3a and 3b, and 270 
category 3c media, with the flow through-cell dissolution apparatus 271 
Dissolution studies were carried out in a flow-through cell dissolution apparatus (Sotax CE7 272 
smart connected to a Sotax piston pump CP7, Sotax, Switzerland) operated in the closed mode 273 
(Fotaki, 2011). Tests were carried in category 3 clinically relevant media (3a and 3b) and in 274 
media from category 3c. A 5mm ruby glass bead was positioned at the bottom of the cell (small 275 
cell: 12 mm diameter; large cell: 22.6 mm diameter). 0.5 mg of AmB API powder was weighed 276 
and mixed with 6.0 g or 0.75 g of 1 mm glass beads, for the large or small cell, respectively, 277 
and were placed into the cell filling the conical part. Glass fibre filters (GF/D, GF/F) were 278 
positioned at the top of the cell. Two different hydrodynamic conditions were tested: i. High 279 
velocity: small cell with a flow rate of 35 mL/min (average linear velocity 0.52 cm/s) and ii. 280 
Low velocity: large cell with a flow rate of 16 mL/min (average linear velocity 0.07 cm/s). 50 281 
mL of test medium were placed into the reservoir under constant stirring at 37°C. 0.5 mL 282 
samples were collected at specific time points up to 8 hours and volume was replaced with 283 
fresh medium. Dissolution studies were also performed with 5 mg (high dose) of AmB in 284 
category 3b PBS medium without BSA under both velocity conditions. Samples were treated 285 
and analysed as described in section 2.3 and the %AmB dissolved over time was calculated. 286 
All experiments were performed in triplicate. 287 
2.9. Treatment of dissolution data 288 
Treatment of dissolution data was described previously (Diaz de Leon-Ortega et al., 2018). 289 
Briefly, AmB dissolution profiles were corrected for degradation using the corresponding 290 
degradation rate constants with Equation 2. 291 
𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑(𝑡) =  𝐶𝑡 +  𝑘𝑑𝑒𝑔 ∗  𝐴𝑈𝐶0−𝑡  Eq 2 292 
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where 𝐶𝑡 is the observed concentration at time 𝑡, 𝐴𝑈𝐶0−𝑡 is the Area Under the Observed 293 
Concentration – Time Curve from time 0 to time 𝑡 and 𝑘𝑑𝑒𝑔 is the degradation rate constant 294 
obtained from the degradation experiments.  295 
The corrected dissolution profiles were calculated based on 𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑(𝑡) and a first order curve 296 
fitting (Eq 3) was performed in order to obtain the dissolution rate constant (Graph Pad Prism 297 
7, Graph Pad Software, Inc., USA). 298 
𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑(𝑡) =  𝑋𝑚𝑎𝑥 ∗ (1 − 𝑒
−𝑘𝑑𝑖𝑠𝑠𝑡)  Eq 3 299 
where 𝑘𝑑𝑖𝑠𝑠is the dissolution rate constant, 𝑋𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑(𝑡) is the corrected percent dissolved at 300 
time t and 𝑋𝑚𝑎𝑥 is the maximum corrected percent dissolved. 301 
2.10. Statistical analysis 302 
Equation 4 was used to analyse the DoE of the category 3a clinical relevant media development. 303 
𝑦 =  𝜇 + 𝐴 + 𝐵 + 𝐶 + 𝐴 ∗ 𝐵 + 𝐴 ∗ 𝐶 + 𝐵 ∗ 𝐶  Equation 4 304 
where 𝑦 is the response (AmB solubility), 𝜇 is the total mean; 𝐴, 𝐵 and 𝐶 are the main factors 305 
(buffer, BS concentration and PL concentration, respectively); 𝐴 ∗ 𝐵, 𝐴 ∗ 𝐶 and 𝐵 ∗ 𝐶 are the 306 
2 level interactions. Buffer type was represented by a value of -1 for PBS and +1 for KRB. The 307 
coefficients were determined by calculating the main effects and interactions and relating them 308 
to the factor tested (by least square algorithms of DoE) and the substituted equation was used 309 
to calculate the composition of clinically relevant media (targeting AmB solubility plasma 310 
values). 311 
To evaluate the effect of surfactants and BSA on AmB solubility in the category 3a and 3b 312 
clinically relevant media, the standardized effects for surfactants (BS-PL, SLS, CTAB and 313 
Tween 80), BSA presence and its interaction, were calculated and used to construct a Pareto 314 
chart. A factor was significant when the standardized effect (bars) was larger than the line for 315 
statistical significance level (α = 0.05) (vertical line).  316 
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To compare degradation rate constants, a t-test was used to compare two experimental 317 
independent means and a paired t-test to compare two experimental related means (significance 318 
p < 0.05). A multiple linear regression model was used to investigate if the solubility and the 319 
degradation rate constant of AmB in any given medium could be related to any of the 320 
parameters of media characterization: viscosity, pH and buffer capacity (significance p < 0.05).  321 
Data analysis and the DoE (design and analysis) were performed with the statistical software 322 
Statgraphics Centurion XVII (USA).  323 
3. Results and discussion 324 
3.1. Determination of solubility and degradation rate constant of AmB in human plasma 325 
from healthy volunteers 326 
AmB solubility in plasma reached a plateau between 3 – 12 h at a concentration of 32.52 ± 327 
0.98 µg/mL (Figure 2) and the AmB degradation rate constant in plasma was 0.033 ± 0.002 h–328 
1 (degradation half-life ~21 h)  (Table 1). 329 
 330 
3.2. Test media development for evaluation of performance of parenteral drug products  331 
3.2.1. Category 1 media 332 
AmB solubility values in category 1 media, obtained in our previous study, were lower (13.03 333 
- 17.56 µg/mL) than those observed in plasma and the degradation rate constants were not 334 
statistically similar to those observed in plasma (Figure 2, Table 1) (Diaz de Leon-Ortega et 335 
al., 2018). 336 
3.2.2. Category 2 media 337 
The osmolality of Category 2 media is similar to the osmolality of plasma. The viscosity values 338 
are also similar to those of plasma using a similar method and range of shear rates, to those 339 
presented by Rand et al (Rand et al., 1964) for plasma at 22°C (Table 2).340 
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On the other hand pH is only similar to plasma in the media with BSA but the buffer capacity 341 
was not as high as in plasma. BSA increased the osmolality and the buffer capacity, and kept 342 
the pH at ~7.5. However, when any other component apart from BSA was added, an increase 343 
in the pH and a decrease in the buffer capacity were observed (Table 2).  344 
Addition of BSA, in a concentration range from 1.5 to 4.0% w/v in KRB buffer (category 1 345 
biorelevant media), was reported to increase AmB solubility (Diaz de Leon-Ortega et al., 346 
2018). The addition of biorelevant plasma components, to which AmB is bound in vivo, to the 347 
medium would be expected to increase AmB solubility bringing it closer to its plasma 348 
solubility. AmB concentration profiles in category 2 media show a decrease in AmB solubility 349 
compared to its solubility in KRB BSA 4.0% w/v (category 1 media) and plasma (Figure 2). 350 
In the concentrations utilized for media development, PL and CH are not soluble (NCBI, 2019; 351 
Sigma-Aldrich, 2019); this might be counterproductive to AmB solubilisation, as the 352 
components need to be in solution in order to dissolve AmB. When CH or BS-PL are present 353 
in the media without BSA the AmB solubility values are the lowest of all the values measured 354 
in all the tested media (Figure 2). In the media where BSA is present along with BS-PL or BS-355 
PL CH, regardless of its concentration, AmB solubility is slightly higher than in these media 356 
without BSA, but lower than the solubility values measured in media with only BSA (Figure 357 
2). It has been reported that BSA is capable of binding bile salts (Farruggia and Picó, 1999; 358 
Green et al., 1971; Pico and Houssier, 1989), cholesterol (Sankaranarayanan et al., 2013; Zhao 359 
and Marcel, 1996) and phospholipids (Jonas, 1976). The results suggest that, rather than CH 360 
or BS-PL having an additive effect to BSA on the solubility of AmB, BSA is hindering 361 
solubilisation by the biorelevant components added to the medium, while at the same time the 362 
biorelevant components are reducing the solubilising effect of BSA on AmB. Only in the 363 
medium with the highest BSA concentration (KRB BS PL BSA 8.0% w/v) AmB solubility was 364 
increased, but still it was lower than in the medium with only BSA 4.0% w/v (category 1 365 
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biorelevant medium). As category 2 media failed to produce better solubility values than 366 
category 1 media, no further studies were performed with these media. 367 
3.2.3.1. Category 3a media 368 
The concentrations of BS and PL in the medium were the only significant factors identified in 369 
the analysis of AmB solubility for the development of category 3a media (Figure 3). 370 
Equation 5 was obtained from the DoE analysis and was used to predict the concentrations of 371 
BS and PL in both KRB and PBS to produce AmB solubility values similar to those observed 372 
in plasma (clinically relevant).  373 
𝑆𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦 (𝜇𝑔/𝑚𝐿) = 5.56 − 2.09 ∗ 𝐵𝑢𝑓𝑓𝑒𝑟 + 0.33 ∗ 𝐵𝑆(𝑚𝑀) + 0.04 ∗ 𝑃𝐿(𝑚𝑀) +374 
0.29 ∗ 𝐵𝑢𝑓𝑓𝑒𝑟 ∗ 𝐵𝑆(𝑚𝑀) + 0.81 ∗ 𝐵𝑢𝑓𝑓𝑒𝑟 ∗ 𝑃𝐿(𝑚𝑀) + 0.18 ∗ 𝐵𝑆(𝑚𝑀) ∗ 𝑃𝐿(𝑚𝑀) (Eq 375 
5). 376 
The predicted concentrations of BS and PL were BS 20.0 mM PL 4.0 mM for KRB BSA 4.0% 377 
w/v and BS 19.7 mM PL 7.9 mM for PBS BSA 4.0% w/v. The media characterization showed 378 
that the presence of BSA increases the buffer capacity, the osmolality and the pH (in KRB); 379 
similar to the effects noted in category 2 media (Table 2). Osmolality was similar to that of 380 
plasma only for the media prepared without BSA (the concentration of BS-PL had a high 381 
impact on the osmolality and when BSA was added, osmolality increased up to 425 mOsm/L). 382 
The pH value was only similar to that of plasma for the medium prepared in PBS, with the 383 
buffer capacity being only statistically similar to the plasma value in PBS BS 19.8 mM PL 7.9 384 
mM BSA 4.0% w/v. Degradation rate constants were not statistically similar to that observed 385 
in plasma except in the KRB BS 20.0 mM PL 4.0 mM medium (Table 1). In both buffers, the 386 
presence of BSA resulted in faster degradation of AmB than in the media without BSA. The 387 
higher AmB degradation rate constant values in these media could potentially be due to the 388 
absence of plasma components which could reduce the AmB degradation. 389 
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AmB solubility values in the media with BSA were lower than those observed in plasma, but 390 
in the media without BSA, AmB solubility values were similar to those observed in plasma 391 
(clinically relevant) (Figure 4).  392 
The predicted BS and PL concentrations to attain clinically relevant solubility were much 393 
higher than the initial exploration ranges. Thus the effects of BS - PL on the solubilising 394 
potential of BSA and vice versa were not captured in the predicted media compositions as the 395 
equation was not validated outside of these exploration ranges. However, the effect of BSA in 396 
the first place seems to have been immaterial in equation 3.5, as clinically relevant solubility 397 
was achieved without inclusion of BSA in the media. 398 
3.2.3.2. Category 3b: clinically relevant media 399 
The CMC of SLS and CTAB in water is 8.1 mM and 1.0 mM, respectively (Attwood and 400 
Florence, 1983). The CMC of charged surfactants tends to decrease in a medium where the 401 
ionic strength is high, such as in saline buffers like PBS and KRB (Thongngam and 402 
McClements, 2005). The CMC of SLS in PBS and KRB was 1.3 ± 0.0 mM and 1.4 ± 0.2 mM, 403 
respectively and the CMC of CTAB in PBS and KRB was 0.9 ± 0.0 mM and 0.2 ± 0.0 mM, 404 
respectively. The surfactant concentrations selected for the solubility studies were above their 405 
CMC. CTAB was not soluble at 100.0 mM and KRB CTAB 50.0 mM BSA 4.0% w/v medium 406 
gelatinized, thus, AmB solubility could not be measured in these media. Figure 5 shows the 407 
AmB solubility in the various category 3b media with and without BSA. 408 
The apparent AmB concentration, even with the highest surfactant concentration, was limited 409 
by the AmB amount added ~ 1.0 mg, hence, the concentration could not be higher than ~100.0 410 
μg/mL .The charged surfactants (anionic and cationic) solubilised more AmB than the non-411 
ionic surfactant despite the fact that AmB is a hydrophobic molecule (log P 0.8 (Sigma-Aldrich, 412 
2015)). AmB, as an amphoteric molecule with two pKa values (pKa1 = 5.5, pKa2 = 10.0) will 413 
be charged at pH 7, thus, the interaction between its charges and those of the surfactant would 414 
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promote contact of the molecules leading to solubilisation of the drug. Similar to category 2 415 
and 3a media observations, BSA presence in the media decreased AmB solubility. It has been 416 
reported that BSA binds to SLS, CTAB and Triton X-100 (non-ionic surfactant) with with the 417 
weakest binding observed for Triton X-100 (De et al., 2005; Gull et al., 2009; Valstar et al., 418 
2000). Figure 6 shows the effect of surfactants (in both category 3a and 3b media) and BSA on 419 
AmB solubility. 420 
The surfactant presence has a statistically significant positive effect on AmB solubility, 421 
whereas BSA and the interaction between BSA and surfactant have a negative effect. The 422 
results suggest that the presence of BSA and the surfactant alone in the medium, solubilise 423 
AmB (Diaz de Leon-Ortega et al., 2018), but when both are in the medium, they interfere with 424 
each other preventing AmB solubilisation and leading to a decrease in the solubility compared 425 
to the solubility reached in the medium with the surfactant alone. The ability of BSA to interfere 426 
with several types of molecules (BS, PL, CH, SLS, CTAB, Tween 80, as found in this study) 427 
has to be taken into account when a biorelevant or clinically relevant medium, incorporating 428 
BSA, is developed. The required concentration of other components with surfactant/solublising 429 
activity could be under-estimated due to protein-surfactant interactions, leading to an 430 
unintended reduction in API solubility. Among the media with the different surfactants tested, 431 
only media which included SLS resulted in clinically relevant solubility values of AmB in KRB 432 
and PBS either with or without BSA. 433 
The compositions of media based on either KRB or PBS with BSA were calculated to target 434 
an AmB clinically relevant solubility value (based on the single point solubility studies). The 435 
calculated compositions of the media to reach AmB solubility values similar to the observed 436 
plasma value were KRB SLS 30.0 mM BSA 4.0% w/v and PBS 60.0 mM BSA 4.0% w/v. The 437 
media composition without BSA could not be obtained directly by just removing BSA from 438 
the media as AmB solubility would be extremely high (Figure 5). Therefore, lower 439 
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concentrations of SLS (0.1 – 4.0 mM) were tested in PBS and KRB to find the appropriate 440 
concentration for clinically relevant AmB solubility values without BSA. The SLS 441 
concentrations where the AmB solubility was similar to that observed in plasma were 1.5 mM 442 
for KRB and 1.4 mM for PBS. In the clinically relevant media developed with SLS, the 443 
presence of BSA did not affect the viscosity but increased the buffer capacity and the 444 
osmolality as in category 3a media (Table 2). AmB degradation rate constants were not 445 
statistically similar to that observed in plasma, and were lowest in media composed of SLS 446 
alone in buffer solution, which can be considered minimal (Table 1). The AmB degradation 447 
rate constants in media with BSA were significantly higher than in the media without BSA. 448 
This effect could be related to observations found in category 1 media (Table 1) where an 449 
increasing BSA concentration had a positive effect on the degradation rate constant. The results 450 
of the solubility studies in the developed category 3b media with and without BSA are 451 
presented in Figure 7. It can be observed that the AmB concentration profiles in the category 452 
3b media are similar to that observed in plasma. 453 
3.2.3.3. Category 3c media 454 
As solubility data in plasma was only available from plasma obtained from healthy subjects, a 455 
target solubility value for hypoalbuminaemic plasma was not available. This section therefore 456 
represents characterisation of media evolved from category 3b as potential candidates for 457 
further patient-centric media development. The composition of the media was as follows: a) 458 
PBS SLS 60.0 mM BSA 2.0% w/v, b) PBS SLS 30.0 mM BSA 2.0% w/v to reflect a reduction 459 
of the inhibition of BSA on SLS solubilisation of AmB (observed during category 2 and 3a and 460 
3b media development) when the lower BSA concentration was used and c) PBS SLS 30.0 mM 461 
BSA 4.0% w/v to explore the reduced potential for SLS solubilisation which might better 462 
reflect a potentially lower solubility in hypoalbuminaemic plasma. These 3 media had 463 
characteristics similar to healthy plasma (Table 2) apart from a reduced buffer capacity (p < 464 
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0.05) and slightly lower pH. The AmB degradation rate constants in media with BSA 2.0% w/v 465 
are apparently lower than those obtained in media with BSA 4.0% w/v (category 3b and 3c) 466 
but the difference was not statistically significant. Only the degradation rate constant in PBS 467 
SLS 60.0 mM BSA 2.0% w/v was statistically similar to that observed in plasma. The results 468 
of the single point (12h) AmB solubility studies in these media were: a) PBS SLS 60.0 mM 469 
BSA 2.0% w/v = 65.57 ± 4.98 µg/mL, b) PBS SLS 30.0 mM BSA 2.0% w/v = 25.84 ± 0.97 470 
µg/mL, c) PBS SLS 30.0 mM BSA 4.0% w/v = 19.77 ± 0.29 µg/mL. This supports the 471 
hypothesis that BSA interferes with the action of the surfactants, in this case SLS, with the 12 472 
h concentrations highest and lowest in the media with SLS 60.0 mM and BSA 2.0% w/v and 473 
SLS 30.0 mM and BSA 4.0% w/v, respectively.  474 
3.2.4. Summary and evaluation of the test media 475 
Table 3 presents a summary and an evaluation of solubility, degradation rate constant and 476 
media characterization in comparison with the parameters obtained/reported in plasma. 477 
Although category 1 media (Diaz de Leon-Ortega et al., 2018) was not clinically relevant for 478 
solubility or degradation, this media could be useful to investigate the impact of albumin 479 
concentration on poorly soluble and highly – protein bound drugs as demonstrated for AmB in 480 
terms of solubility, degradation and pharmacological activity (Diaz de Leon-Ortega et al., 481 
2018). Clinically relevant AmB solubility values are achieved by using biorelevant surfactants 482 
in category 3a media without BSA. These media could be used for in vitro release tests of AmB 483 
lipid-based formulations and also, these media with BSA could be used in order to explore 484 
effects of BSA on release from the formulation. Clinically relevant AmB solubility values were 485 
achieved in all the category 3b media developed. Category 3b media without BSA could be 486 
proposed as a basis for the development of appropriate media for compendial release tests, as 487 
they easier to prepare and the degradation of the drug is minimal (Table 1). For category 3c 488 
media, there were no reference values for solubility, degradation and media characterization 489 
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due to the lack of availability of hypoalbuminaemic plasma. Assuming that AmB solubility 490 
will be lower in hypoalbuminaemic plasma compared to healthy plasma, PBS SLS 30.0 mM 491 
BSA 4.0% w/v is a good candidate for the development of simulated hypoalbuminaemic 492 
plasma as the AmB solubility at 12 h in this medium was lower than the clinically relevant 493 
value.  494 
The multiple linear regression analysis showed that neither the solubility nor the degradation 495 
rate constant could be related to any of the properties of media characterization shown in Table 496 
2 (p > 0.05).  497 
3.4. Dissolution studies of AmB with the flow through cell apparatus in clinically relevant 498 
media 499 
Dissolution studies were performed in media with clinically relevant AmB solubility from 500 
category 3a and 3b, and in each of the media explored in category 3c (Figure 8).  501 
Clinically relevant AmB solubility values were obtained in PBS and in KRB, but the media 502 
with PBS were selected for dissolution studies due to their reduced medium complexity 503 
(compared to KRB). First order equation parameters of AmB, for dissolution profiles 504 
(corrected for degradation) fitted to Eq 3, are listed in Table 4. 505 
Dissolution profiles in PBS BS 19.8 mM PL 7.9 mM could not be modeled using Eq 3 in either 506 
low or high velocity conditions. In the low velocity environment, the %AmB dissolved reached 507 
a maximum value of 44.93 ± 2.89% at 3.0 h and then started to decrease until the end of the 508 
experiment (8 h). This could indicate that mixed micelles of BS – PL need a stronger agitation 509 
(as in the bottle/stirrer setup used in the solubility and degradation studies) for a notable, 510 
durable effect on AmB dissolution. There was no reduction over time of the AmB percent 511 
dissolved when the test was conducted at high velocity, however in this situation there was no 512 
discernible plateau and rather a very gradual increase in % dissolved over time, prohibiting 513 
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fitting of Eq 3 to the data. In summary, AmB dissolution is greater under the high velocity 514 
conditions in the clinically relevant category 3a medium (Figure 8). 515 
There was a statistically significant negative effect of velocity on the dissolution rate constant 516 
for the 0.5 mg dose and a positive effect on maximum % dissolved on the 5 mg dose; however, 517 
these differences were of low practical significance and possibly reflect process variability.  518 
The %AmB dissolved in the experiment with the high dose of AmB reached a plateau value of 519 
around 20%, due to the solubility of AmB in this medium (~30 µg/mL), (Figure 8). In category 520 
3b medium with BSA, with respect to velocity, the low and high velocity conditions had little 521 
effect on AmB dissolution in comparison to medium composition. 522 
The velocity regimes in the flow through apparatus (average velocities: low velocity: 0.07 cm/s, 523 
high velocity: 0.52 cm/s), are low overall in comparison to the bottle/stirrer set up. A faster 524 
dissolution and a higher %AmB dissolved is observed in the category 3b medium with BSA 525 
compared to that observed in the medium without BSA. This could be attributed to increased 526 
wetting/dispersion from either the BSA or the SLS. PBS SLS 1.4 mM is therefore suggested 527 
as a simplified medium that could be used in compendial dissolution testing of AmB parenteral 528 
formulations, as clinically relevant AmB solubility values were obtained in this medium.  529 
In category 3c media, the %AmB dissolved in PBS SLS 60.0 mM BSA 2.0% w/v started to 530 
decrease before the 1.5 h sample in the low velocity conditions. The results suggest that the 531 
agitation required to keep SLS, BSA and AmB in solution at these concentrations was higher 532 
as the decrease was not observed when the high velocity conditions were used. The highest 533 
%AmB dissolved was observed in PBS SLS 60.0 mM BSA 2.0% w/v and the lowest in PBS 534 
SLS 30 mM BSA 4.0% w/v, again supporting the hypothesis that BSA binds the surfactants 535 
and prevents their interaction with AmB. The AmB dissolution profiles in PBS SLS 30.0 mM 536 
BSA 2.0% w/v and PBS SLS 60 mM BSA 4.0% w/v were similar, probably due to the same 537 
ratio of SLS/BSA in these two media. Velocity had a negative effect only on the dissolution 538 
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rate of AmB in PBS SLS 30.0 mM BSA 2.0% w/v whereas this was not observed in the AmB 539 
dissolution in the other category 3c media. Based on the presumption of lower AmB solubility 540 
in hypoalbuminaemic plasma, the results suggest that the most suitable clinically relevant 541 
medium to simulate hypoalbuminaemic conditions is PBS SLS 30 mM BSA 4.0% w/v; 542 
confirmation with solubility studies in plasma from hypoalbuminaemic patients would be 543 
needed. As the dissolution profiles were calculated based on concentrations corrected 544 
accounting for AmB degradation, the degradation rate constant was not a factor to be 545 
considered in the analysis, as it was already taken into account in the profiles. 546 
The dissolution studies provided information on which test media would be suitable for 547 
formulation release studies. For example, some test media were not able to keep AmB 548 
solubilized for the duration of an 8 h test, even after correcting for degradation, despite being 549 
designed to produce clinically relevant solubility values. Furthermore, there is scope for further 550 
exploration of dissolution test conditions in terms of apparatus and hydrodynamic environment 551 
to determine suitably discriminating conditions for dissolution/release testing of parenteral 552 
formulations. 553 
Summarizing, in order to develop a clinically relevant test for a poorly soluble, degradation-554 
susceptible and highly protein-bound drug for parenteral administration, based on the current 555 
work focussed on AmB, the following steps are proposed: 556 
1. Determine API solubility in the target fluid, in this case plasma 557 
2. If the API is highly protein-bound, a suitable protein should be incorporated in the medium 558 
or a surfactant able to match the desired solubility; and if both are going to be incorporated, 559 
investigate the effect of any interaction between them on the solubility of the drug 560 
3. Determine the degradation rate of the API in the media investigated for further correction of 561 
dissolution/release profiles 562 
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4. Test the API dissolution/solubility behaviour in the test media and hydrodynamic conditions 563 
that will be used in the formulation dissolution/release testing, as stability/solubility problems 564 
will be easier to be identified using the API alone before the drug dissolution/ release testing 565 
from the formulation. 566 
 567 
4. Conclusions 568 
AmB is an antifungal drug that is highly bound to plasma proteins, including albumin and 569 
lipoproteins. It is administered to patients intravenously as lipid-based formulations. Therefore, 570 
a test medium to assess the release profile of the drug from its lipid-based parenteral 571 
formulations that can provide clinically relevant results is desirable. 572 
In this study we have developed biorelevant media based on plasma composition and clinically 573 
relevant dissolution media based on the solubility of AmB in plasma. This was achieved by 574 
using saline buffers, surfactants (biorelevant and synthetic) and BSA. Clinically relevant AmB 575 
solubility was not achieved in the biorelevant media. It was shown that addition of BSA in the 576 
medium generally induces a faster degradation of AmB. Another role of BSA in the media is 577 
the capability to interfere with the solubilizing activity of almost all of the components that 578 
were added to the media. Instead of resulting in an improved AmB solubility by combining 579 
surfactants with BSA, the opposite effect was observed. This has to be taken into consideration 580 
for development of in vitro test media where the protein binding is an important feature. Based 581 
on the dissolution study results, medium complexity and minimal degradation, PBS SLS 1.4 582 
mM is suggested as an option for development of release tests for AmB formulations. For the 583 
simulated hypoalbuminaemic media, PBS SLS 30 mM BSA 4.0% w/v is suggested as a 584 
potential candidate medium for further (patient centric) medium development, although future 585 
experiments with hypoalbuminaemic plasma are needed to confirm the effect of 586 
hypoalbuminaemia on solubility. Guidance is given for the initial stages of the development of 587 
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a clinically relevant in vitro dissolution/release test for parenteral formulations. Development 588 
of clinically relevant media is a first step for developing clinically relevant dissolution/ release 589 
tests with a view to obtaining in vitro data predictive of the in vivo behaviour of the formulation 590 
and the drug. 591 
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Table 1. Degradation rate constants of AmB in plasma, category 1 and 3 media. (Mean ± SD; 713 
n = 3). 714 
Type of medium Medium 𝒌𝒅𝒆𝒈 (h
-1) 
Plasma Plasma 0.033 ± 0.002  
Category 1 KRB BSA 1.5% w/v 0.026 ± 0.000 
(Diaz de Leon-
Ortega et al., 
2018) 
KRB BSA 2.0% w/v 0.065 ± 0.005 
(Diaz de Leon-
Ortega et al., 
2018) 
KRB BSA 3.0% w/v 0.065 ± 0.021 
(Diaz de Leon-
Ortega et al., 
2018) 
KRB BSA 4.0% w/v 0.095 ± 0.003 
(Diaz de Leon-
Ortega et al., 
2018) 
Category 3 3a KRB BS 20.0 mM PL 4.0mM 0.023 ± 0.010  
KRB BS 20.0 mM PL 4.0 mM BSA 4.0% w/v 0.060 ± 0.008 
PBS BS 19.8 mM PL 7.9 mM 0.048 ± 0.006 
PBS BS 19.8 mM PL 7.9 mM BSA 4.0% w/v 0.097 ± 0.021 
32 
 
3b KRB SLS 1.5mM 0.009 ± 0.007 
KRB SLS 30.0mM BSA 4.0% w/v 0.038 ± 0.001 
PBS SLS 1.4 mM 0.005 ± 0.003 
PBS SLS 60.0 mM BSA 4.0% w/v 0.052 ± 0.015 
3c PBS SLS 30.0 mM BSA 2.0% w/v 0.062 ± 0.014 
PBS SLS 30.0 mM BSA 4.0% w/v 0.082 ± 0.015  





Table 2. Media composition and media characterization. Plasma characterization is included (Mean ± SD; n = 3 for Vis and BC HCl). 717 
Category Medium Osm 
(mOsm/L) 
Vis (cPs) pH BC HCl 
(mEq/L/pH) 
Plasma Plasma 275 - 300 
(Dasgupta and 
Wahed, 2014) 
3.5 (Rand et 
al., 1964) 
7.34 ± 0.04 
(Shepherd, 
1979) 
16.1 ± 0.9 (Ellison 
et al., 1958) 
Category 1 KBR BSA 4.0% w/v 308 (Diaz de 
Leon-Ortega et 
al., 2018) 
4.0 ± 0.0 
(Diaz de 
Leon-Ortega 
et al., 2018) 
7.36 (Diaz de 
Leon-Ortega et 
al., 2018) 
12.0 ± 1.2 
Category 2 KRB BS 12.0 μM PL 2.5 mM 278 5.0 ± 0.1 8.64 1.5 ± 0.0 
KRB BS 12.0 μM PL 2.5 mM CH 4.5 mM 273 5.0 ± 0.1 8.79 1.5 ± 0.1 
KRB BS 12.0 μM PL 2.5 mM BSA 2.0% 
w/v 
314 5.2 ± 0.1 7.79 7.8 ± 0.0 
KRB BS 12.0 μM PL 2.5 mM CH 4.5 mM 
BSA 4.0% w/v 
306 5.0 ± 0.1 7.80 7.5 ± 0.2 
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KRB BS 12.0 μM PL 2.5 mM BSA 8.0% 
w/v 
351 5.2 ± 0.0 7.65 7.7 ± 0.0 
Category 3 3a KRB BS 20.0 mM PL 4.0 mM 310 4.8 ± 0.1 8.25 1.7 ± 0.0 
PBS BS 19.8 mM PL 7.9 mM 330 4.7 ± 0.1 7.36 6.1 ± 0.1 
KRB BS 20.0 mM PL 4.0 mM BSA 4.0% 
w/v 
415 5.0 ± 0.1 8.50 5.2 ± 0.1 
PBS BS 19.8 mM PL 7.9 mM BSA 4.0% 
w/v 
425 4.9 ± 0.1 7.18 14.2 ± 0.8 
3b KRB SLS 1.5 mM 289 4.6 ± 0.1 8.54 1.2 ± 0.0 
PBS SLS 1.4 mM 280 4.4 ± 0.1 7.43 5.6 ± 0.1 
KRB SLS 30.0 mM BSA 4.0% w/v 350 5.0 ± 0.1 7.84 7.9 ± 0.1 
PBS SLS 60.0 mM BSA 4.0% w/v 325 5.2 ± 0.1 7.56 10.3 ± 0.2 
3c PBS SLS 30.0 mM BSA 2.0% w/v 300 4.8 ± 0.0 7.10 9.3 ± 0.2 
PBS SLS 30.0 mM BSA 4.0% w/v 297 4.6 ± 0.0 7.18 9.6 ± 0.6 
PBS SLS 60.0 mM BSA 2.0% w/v 302 4.9 ± 0.1 7.04 11.6 ± 0.3 
Osm: Osmolality, Vis: Viscosity, BC HCl: buffer capacity determined with HCl.  718 
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Table 3. Evaluation of solubility, degradation rate constant and media characterization in comparison with the parameters obtained/reported in 719 
plasma. ND = not determined due to data unavailable for comparison,  = not biorelevant,  = biorelevant.  720 
Category Medium CRS CRD Osm Vis pH BC HCl Medium 
Complexity 
Category 1 KRB BSA 4.0% w/v (Diaz de Leon-Ortega et al., 
2018) 
No No     1 
Category 3a KRB BS 20.0 mM PL 4.0 mM Yes Yes     4 
PBS BS 19.8 mM PL 7.9 mM Yes No     3 
KRB BS 20.0 mM PL 4.0 mM BSA 4.0% w/v No No     4 
PBS BS 19.8 mM PL 7.9 mM BSA 4.0% w/v No No     3 
Category 
3b 
KRB SLS 1.5 mM Yes No     2 
PBS SLS 1.4 mM Yes No     1 
KRB SLS 30.0 mM BSA 4.0% w/v Yes No     2 
PBS SLS 60.0 mM BSA 4.0% w/v Yes No     1 
Category 3c PBS SLS 30.0 mM BSA 2.0% w/v ND ND ND ND ND ND 1 
PBS SLS 30.0 mM BSA 4.0% w/v ND ND ND ND ND ND 1 
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PBS SLS 60.0 mM BSA 2.0% w/v ND ND ND ND ND ND 1 
CRS: AmB clinically relevant solubility, CRD: AmB clinically relevant degradation rate constant, Osm: osmolality, Vis: viscosity, BC HCl: buffer 721 




Table 4. Parameters obtained after fitting (Eq 3) of %AmB dissolution profiles in category 3b clinically relevant media and 3c media with the flow 724 
through cell apparatus (Mean ± SD, n = 3). 725 
Type of medium Medium Flow/velocity 𝒌𝒅𝒊𝒔𝒔  (h
-1) 𝑿𝒎𝒂𝒙 (%) R
2 AIC 
Category 3b PBS SLS 1.4 mM Low 
dose 
Low 2.39 ± 0.13 36.28 ± 0.59 0.94 ± 0.00 50.03 ± 0.29 
PBS SLS 1.4 mM High 
dose 
Low 2.98 ± 0.74 16.75 ± 1.16 0.91 ± 0.01 38.77 ± 2.28 
PBS SLS 60.0 mM 
BSA 4.0% w/v 
Low 3.65 ± 1.59 52.79 ± 5.52 0.91 ± 0.05 63.05 ± 3.77 
PBS SLS 1.4 mM Low 
dose 
High 1.88 ± 0.26 38.66 ± 2.08 0.93 ± 0.02 53.94 ± 4.06 
PBS SLS 1.4 mM High 
dose 
High 2.50 ± 0.40 19.47 ± 0.81 0.92 ± 0.01 40.40 ± 1.32 
PBS SLS 60.0 mM 
BSA 4.0% w/v 
High 5.60 ± 1.30 62.86 ± 5.22 0.91 ± 0.10 63.03 ± 12.28 
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Category 3c PBS SLS 30.0 mM 
BSA 2.0% w/v 
Low 4.21 ± 0.96 53.38 ± 9.94 0.96 ± 0.05 50.47 ± 9.28 
PBS SLS 30.0 mM 
BSA 2.0% w/v 
High 2.33 ± 0.35 63.07 ± 3.48 0.94 ± 0.01 63.20 ± 1.21 
PBS SLS 30.0 mM 
BSA 4.0% w/v 
High 7.66 ± 5.39 37.22 ± 8.20 0.89 ± 0.04 57.06 ± 3.45 
PBS SLS 60.0 mM 
BSA 2.0% w/v 
High 6.43 ± 2.87 78.38 ± 0.50 0.96 ± 0.01 63.08 ± 3.31 
 726 
R2: correlation coefficient, AIC: Akaike Information Criterion. 727 
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Figures’ captions 728 
 729 
Figure 1. Categories of media development for evaluation of performance of parenteral drug 730 
products. 731 
Figure 2. Solubility study of AmB in category 2 media: AmB concentration as a function of 732 
time in plasma and category 2 media (Mean ± SD; n= 3). KRB BSA 4.0% w/v solubility 733 
(category 1 medium) and KRB BS 12.0 μM PL 2.5 mM BSA 8.0% w/v were added for 734 
comparison purposes (Diaz de Leon-Ortega et al., 2018). BSA concentration is in % w/v units. 735 
Figure 3. Pareto chart for the standardized effects of the main factors and 2 level interactions 736 
of the analysis of AmB solubility in media with BS, PL and different types of buffer. The black 737 
horizontal line represents the significance threshold for the effects. The factors with an effect 738 
(bar) larger than the threshold are statistically significant. 739 
Figure 4. Solubility study of AmB in category 3a media: AmB concentration as a function of 740 
time in category 3a media with and without BSA (Mean ± SD; n= 3). BSA concentration is in 741 
% w/v units. AmB plasma solubility was added for comparison purposes [solid lines represent 742 
the media with BSA 4.0% w/v; dashed lines represent the media without BSA]. 743 
Figure 5. Solubility study of AmB in media with surfactants for the development of category 744 
3b media: AmB concentration in PBS or KRB with 5.0, 50.0 and 100.0 mM concentrations of 745 
SLS, CTAB or Tween with and without BSA 4.0% w/v at 12 h (Mean ± SD; n= 3). Black 746 
horizontal line represents the AmB solubility value in human plasma from healthy subjects. 747 
Figure 6. Pareto charts for the standardized effects of the main factors and 2 level interactions 748 
of the analysis of AmB solubility in media with surfactants and BSA 4.0% w/v. The black 749 
horizontal line represents the significance threshold for the effects. The factors with an effect 750 
(bar) larger than the threshold are statistically significant. 751 
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Figure 7. Solubility study of AmB in category 3b media: AmB concentration as a function of 752 
time in the category 3b clinically relevant media with and without BSA (mean ± SD; n= 3). 753 
AmB plasma solubility was added for comparison purposes. The BSA concentration is in % 754 
w/v units. 755 
Figure 8. %AmB dissolved as a function of time in the category 3a and 3b clinically relevant 756 
media and in category 3c media with the flow through cell apparatus at 37°C (mean ± SD; n= 757 
3). High dose = 5 mg of AmB. BSA concentration is in % w/v units. Points represent observed 758 
data and the lines the first order (Eq 3) equation fittings. 759 
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